Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 118
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the efficacy, pharmacokinetics, safety, and immunogenicity of abatacept after subcutaneous and intravenous administration in Japanese participants with active rheumatoid arthritis and inadequate response to methotrexate.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Intravenous (IV) abatacept intervention 2: Subcutaneous (SC) abatacept
Intervention descriptions: intervention 1: IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141. intervention 2: Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks

Protocol document: